articleAnnals of OncologyOct 10, 2022HYBRID OA

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

CECharles E. GeyerJEJudy E. GarberRDRichard D. GelberGYGreg YothersMTManuel Taboada

UPMC Hillman Cancer Center · NRG Oncology · +107 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS).…

Citation impact

437
total citations
FWCI
40.14
Percentile
100%
References
35
Citations per year

Authors

609

Topics & keywords

Topics
Keywords
  • Medicine
  • Olaparib
  • Internal medicine
  • Oncology
  • Placebo
  • Hazard ratio
  • Breast cancer
  • Confidence interval
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding